Evidence map›Paper›PMID 32715099›Full record

ArticleOsteoporosis and sarcopenia2020

Factors associated with osteoporosis medication use in Japanese patients with rheumatoid arthritis: Results from the Institute of Rheumatology Rheumatoid Arthritis cohort study.

Masanori Nakayama, Takefumi Furuya, Eisuke Inoue, Eiichi Tanaka, Katsunori Ikari, Atsuo Taniguchi, Hisahi Yamanaka, Masayoshi Harigai

Abstract read
In one paragraph

Article in Osteoporosis and sarcopenia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Masanori NakayamaDepartment of Orthopaedic Surgery, School of Medicine, International University of Health and Welfare (IUHW), Chiba, Japan.
Takefumi FuruyaDepartment of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Eisuke InoueDepartment of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Eiichi TanakaDepartment of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Katsunori IkariDepartment of Orthopedic Surgery, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Atsuo TaniguchiDepartment of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Hisahi YamanakaDepartment of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Masayoshi HarigaiDepartment of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aimed to evaluate factors associated with osteoporosis medication use in Japanese patients with rheumatoid arthritis (RA).

methodsPatients with RA who enrolled in our cohort completed self-administered questionnaires which included questions regarding their osteoporosis medications. Logistic regression was used to determine the association of variables with the use of these medications.

resultsAmong 5660 Japanese patients with RA who responded to the questionnaires (mean age, 61.8 years; 86.0% female), 1983 patients (35.0%) and 1211 patients (21.4%) reported taking osteoporosis medications and antiresorptive agents, respectively. In multivariate models, age, female sex, lower body mass index (BMI), self-reported fracture history, Japanese Health Assessment Questionnaire-Disability Index (JHAQ-DI), daily dosage of prednisone (PSL), weekly dosage of methotrexate (MTX), and concomitant use of hypertension and hyperlipidemia medications were significantly associated with the use of osteoporosis medications (P < 0.05). Among women with RA, the use of hypertension medications was significantly correlated with the use of both osteoporosis medications and antiresorptive agents (P < 0.05).

conclusionsAge, female sex, a lower BMI, duration of RA, self-reported fracture history, JHAQ-DI, daily dosage of PSL, weekly dosage of MTX, and the use of medications for hypertension and hyperlipidemia appear to be associated with the use of osteoporosis medications in Japanese patients with RA.

Indexed as

Antiresorptive agentsJapaneseOsteoporosisRheumatoid arthritis

Identifiers

PMID32715099
PMCPMC7374244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.